Digestive Diseases and Sciences

, Volume 60, Issue 4, pp 1010–1015 | Cite as

Low-Dose Aspirin and Non-steroidal Anti-inflammatory Drugs Increase the Risk of Bleeding in Patients with Gastroduodenal Ulcer

  • Keisuke Kawasaki
  • Koichi Kurahara
  • Shunichi Yanai
  • Shuji Kochi
  • Tadahiko Fuchigami
  • Takayuki Matsumoto
Original Article



Non-steroidal anti-inflammatory drugs (NSAIDs), low-dose aspirin (LDA), non-aspirin antiplatelet medications (APs), and anticoagulant medications (ACs) increase the risk of gastrointestinal bleeding.


To examine whether NSAIDs, LDA, APs, and ACs use is associated with bleeding from gastroduodenal ulcers.


This was a case–control study of patients with endoscopically verified gastroduodenal ulcer diagnosed at our institution from 2004 to 2011. Among 1,611 patients, we identified those who required endoscopic hemostasis for bleeding ulcers as cases. Age-matched, sex-matched, and Helicobacter pylori status-matched patients who did not require therapeutic interventions served as controls. Use of NSAIDs, LDA, APs, and ACs within 2 weeks prior to the endoscopy was compared between cases and controls, and effects on ulcer bleeding were calculated.


We recruited 341 cases and 668 controls. The site and number of ulcers were not different between groups. Multivariate analyses revealed that LDA and NSAIDs, individually, were associated with the increase in the risk of bleeding (OR 1.80 and 95 % CI 1.18–2.75 for LDA; 1.35 and 1.01–1.80 for NSAIDs). In addition, a combination of LDA and NSAIDs or LDA and APs contributed more profoundly to the bleeding (OR 3.59 and 95 % CI 1.19–10.81 for LDA/NSAIDs; OR 6.70 and 95 % CI 1.83–24.50 for LDA/APs). However, ACs, alone or in combination, were not associated with bleeding ulcers.


Both LDA and NSAIDs are risk factors for upper GI bleeding in patients with gastroduodenal ulcer, while ACs are unrelated to the increased risk. The risk of bleeding with LDA may increase with simultaneous use of APs.


Gastroduodenal ulcer Gastrointestinal bleeding Non-steroidal anti-inflammatory drugs Low-dose aspirin Antithrombotic medication 


Conflict of interest



  1. 1.
    Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14–22.CrossRefPubMedGoogle Scholar
  2. 2.
    Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827–830.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731–1738.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Sakamoto C, Suganno K, Ota S, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol. 2006;62:765–772.CrossRefPubMedGoogle Scholar
  6. 6.
    Graham DY, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991:100;1495–1501.Google Scholar
  7. 7.
    Miwa H, Go MF, Sato N. H. pylori and gastric cancer: the Asian enigma. Am J Gastroenterol. 2002;97:1106–1112.CrossRefPubMedGoogle Scholar
  8. 8.
    Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E, Hautekeete ML. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study. Gut. 1991;32:730–734.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769–772.CrossRefPubMedGoogle Scholar
  10. 10.
    Blower AL, Brooks A, Fenn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther. 1997;11:283–291.CrossRefPubMedGoogle Scholar
  11. 11.
    García Rodríguez LA, Catteruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 1998;158:33–39.CrossRefPubMedGoogle Scholar
  12. 12.
    Udd M, Miettinen P, Palmu A, et al. Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case-control study. Scand J Gastroenterol. 2007;42:1395–1403.CrossRefPubMedGoogle Scholar
  13. 13.
    De Abajo FJ, Gil MJ, Bryant V, Timoner J, Oliva B, García Rodríguez LA. Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database. Eur J Clin Pharmacol. 2013;69:691–701.CrossRefPubMedGoogle Scholar
  14. 14.
    Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343:834–839.CrossRefPubMedGoogle Scholar
  15. 15.
    Sørensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218–2224.CrossRefPubMedGoogle Scholar
  16. 16.
    García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123:1108–1115.CrossRefPubMedGoogle Scholar
  17. 17.
    Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22:795–801.CrossRefPubMedGoogle Scholar
  18. 18.
    Graham DY. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol. 1991;6:105–113.CrossRefPubMedGoogle Scholar
  19. 19.
    Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102:760–766.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Keisuke Kawasaki
    • 1
    • 2
  • Koichi Kurahara
    • 2
  • Shunichi Yanai
    • 1
  • Shuji Kochi
    • 2
  • Tadahiko Fuchigami
    • 2
  • Takayuki Matsumoto
    • 1
  1. 1.Division of Gastroenterology, Department of Internal MedicineIwate Medical UniversityMoriokaJapan
  2. 2.Division of GastroenterologyMatsuyama Red Cross HospitalMatsuyamaJapan

Personalised recommendations